Thursday, August 7, 2025
News Health
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health
No Result
View All Result
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health
No Result
View All Result
HealthNews
No Result
View All Result
Home Health News

FDA Approves Drug for Aggressive Glioma

August 6, 2025
in Health News
Share on FacebookShare on Twitter


The FDA has granted accelerated approval to dordaviprone (Modeyso, Jazz Pharmaceuticals) for H3 K27M-mutant diffuse glioma, marking the first time a systemic therapy has been approved for the aggressive glioma subtype.

H3 K27M-mutant diffuse glioma is a grade 4 midline tumor that primarily affects children and young adults. Median survival is about a year. Historically, treatment has been limited to radiation, with few options available after recurrence besides palliative care.

Dordaviprone is a first-in-class oral imipridone that disrupts tumor cell metabolism and increases tumor susceptibility to immune-mediated attack.

Jazz Pharmaceuticals bought Chimerix in early 2025 for almost $1 billion based on dordaviprone’s commercial prospects.

“Dordaviprone has the potential to rapidly become a standard of care for a rare oncology disease and also contribute durable revenue beginning in the near-term,” Jazz CEO Bruce Cozadd, said in a press release at the time.

Approval was based on a pooled analysis of five single-arm studies enrolling 46 adults and four children with recurrent tumors previously treated with radiation, according to a statement from the FDA. Adults received 625 mg once weekly while pediatric patients received lower, weight-adjusted weekly doses. Mutation status was confirmed by immunohistochemistry or sequencing of archival tumor tissue.

The overall response rate was 22%. The median time to response was 8.3 months, and the median duration of response (DOR) was 10.3 months. 

Among 11 patients with objective responses, 73% had a DOR of at least 6 months, and 27% had a DOR of at least 12 months.

Seven of 15 evaluable patients (46.7%) were able to have corticosteroid dose reductions of at least 50%, and performance status improved in six of 34 (20.6%) patients.

Sixty percent of subjects experienced treatment-related, treatment-emergent adverse events (TR-TEAEs), including fatigue (34%), nausea (18%), decreased lymphocyte levels (14%). The most common serious adverse events were hydrocephalus (8%) and nausea (8%). Grade 3 TR-TEAEs occurred in 20%, most commonly fatigue (10%).

One case each of seizure and pulmonary embolism were seen. There were no treatment-related deaths.

The drug’s prescribing information includes warnings and precautions for hypersensitivity, QTc interval prolongation, and embryo-fetal toxicity, according to the FDA statement.

A phase 3 trial is underway to confirm the benefit of dordaviprone for recurrent H3 K27M-mutant diffuse glioma. 

M. Alexander Otto is a physician assistant with a master’s degree in medical science and a journalism degree from Newhouse. He is an award-winning medical journalist who worked for several major news outlets before joining Medscape. Alex is also an MIT Knight Science Journalism fellow. Email: [email protected]



Source link : https://www.medscape.com/viewarticle/fda-approves-drug-aggressive-glioma-2025a1000kxu?src=rss

Author :

Publish date : 2025-08-06 21:30:00

Copyright for syndicated content belongs to the linked Source.

Previous Post

FDA Approves Brain Tumor Drug Targeting New Mutation

Next Post

Extra-strong nicotine pouches packaged like children’s sweets

Related Posts

Health News

Amy has complex PTSD but has seen a psychiatrist once in 10 years

August 7, 2025
Health News

French Fries Singled Out for Diabetes Risk

August 6, 2025
Health News

Extra-strong nicotine pouches packaged like children’s sweets

August 6, 2025
Health News

FDA Approves Brain Tumor Drug Targeting New Mutation

August 6, 2025
Health News

Abstracts Related to Dietary Guidelines Pulled From Meeting, Raising Concerns

August 6, 2025
Health News

Patient Deaths, Inner Scars, and Physicians’ Need to Grieve

August 6, 2025
Load More

Amy has complex PTSD but has seen a psychiatrist once in 10 years

August 7, 2025

French Fries Singled Out for Diabetes Risk

August 6, 2025

Extra-strong nicotine pouches packaged like children’s sweets

August 6, 2025

FDA Approves Drug for Aggressive Glioma

August 6, 2025

FDA Approves Brain Tumor Drug Targeting New Mutation

August 6, 2025

Abstracts Related to Dietary Guidelines Pulled From Meeting, Raising Concerns

August 6, 2025

Patient Deaths, Inner Scars, and Physicians’ Need to Grieve

August 6, 2025

Lithium May Combat Alzheimer’s Disease, Data Suggest

August 6, 2025
Load More

Categories

Archives

August 2025
MTWTFSS
 123
45678910
11121314151617
18192021222324
25262728293031
« Jul    

© 2022 NewsHealth.

No Result
View All Result
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health

© 2022 NewsHealth.

Go to mobile version